The DOI matches its Crossref record.
Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
Open accessAbstract
The "debrisoquine polymorphism" is a clinically important genetic defect of drug metabolism affecting 5-10% of individuals in Caucasian populations. It is inherited as an autosomal recessive trait. A full-length cDNA for human cytochrome P-450db1, the deficient enzyme (also designated P450IID1 for P450 family II subfamily D isozyme 1), has recently been cloned. Leukocyte DNA from "extensive metabolizers" (EMs) or "poor metabolizers" (PMs) of debrisoquine was examined by Southern analysis. Two polymorphic restriction fragments were associated with the PM phenotype when DNAs from 24 unrelated PM and 29 unrelated EM individuals were probed with P-450db1 cDNA after digestion with Xba I restriction endonuclease and Southern blotting: a polymorphic 44-kilobase (kb) fragment was found in 58% of PMs but only in 3.4% of EMs, and a polymorphic 11.5-kb fragment was present in 33% of PMs but in none of the EMs. Seventy-five percent of PMs had either the 44-kb or the 11.5-kb fragment or both. Segregation of these restriction fragment length polymorphisms in the families of six PM probands demonstrated that each of the two fragments is allelic with the 29-kb fragment present in all EM individuals and suggests that they identify two independent mutated allels of the P-450db1 gene (designated P450C2D1). At least a third mutated allele not detected by these restriction fragment length polymorphisms must be present in the population. The Xba I 44-kb fragment and 11.5-kb fragment were in linkage disequilibrium with restriction fragment length polymorphisms generated by four and five additional restriction endonucleases, respectively, which can be used to identify the same mutant alleles for the P-450db1 gene.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
Wrighton, S. A., & Stevens, J. C. (1992) · Critical Reviews in Toxicology · doi:10.3109/10408449209145319 · Cited by 944
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM
Meyer, U. A., & Zanger, U. M. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.269 · Cited by 549
Self-citationMolecular genetics of the P-450 superfamily
Gonzalez, F. J. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90006-n · Cited by 493
Self-citationAoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V, Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81632-5 · Cited by 482
Self-citationPiegorsch, W. W., Weinberg, C. R., & Taylor, J. A. (1994) · Statistics in Medicine · doi:10.1002/sim.4780130206 · Cited by 479
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
Heim, M., & Meyer, U. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)92086-w · Cited by 447
Self-citationBertilsson, L. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00005 · Cited by 432
Pharmacogenetics – five decades of therapeutic lessons from genetic diversity
Meyer, U. A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1428 · Cited by 420
Self-citationThe genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Alv�n, G., Bechtel, P., Iselius, L., & Gundert-Remy, U. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316090 · Cited by 361
Segmental duplications and their variation in a complete human genome
Vollger, M. R., Guitart, X., Dishuck, P. C., Mercuri, L., Harvey, W. T., Gershman, A., Diekhans, M., Sulovari, A., Munson, K. M., Lewis, A. P., et al. (2022) · Science · doi:10.1126/science.abj6965 · Cited by 350
Bioactivation of Halogenated Hydrocarbons by Cytochrome P4502E1
Raucy, J. L., Kraner, J. C., & Lasker, J. M. (1993) · Critical Reviews in Toxicology · doi:10.3109/10408449309104072 · Cited by 265
Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., & Meyer, U. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44890-3 · Cited by 265
Self-citation
Metadata
- Authors
- Skoda, R. C., Gonzalez, F. J., Demierre, A., & Meyer, U. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1988-07
- Volume
- 85
- Issue
- 14
- Pages
- 5240-5243
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2021755256
- Cited by
- 195
- References
- 0
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.